文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

模拟人工胰腺调控重症患者应激性高血糖的疗效与安全性:前瞻性随机对照研究

[Efficacy and safety of simulated artificial pancreas in modulating stress hyperglycemia in critically ill patients: a prospective randomized controlled study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2018-01-01
一句话结论模拟人工胰腺可有效安全调控重症患者应激性高血糖,高强度调控降糖达标率更高但低血糖率也增加。

该前瞻性随机对照研究纳入60例ICU应激性高血糖患者,随机分为优泌林组、低强度组和高强度组各20例,分别采用皮下注射优泌林70/30、模拟人工胰腺低强度(诺和灵R 1/3剂量)和高强度(诺和灵R 2/3剂量)调控血糖。结果显示高强度组平均血糖最低(8.1±2.2 mmol/L)、达标率最高(80.4%)、达标时间最短(17.5±4.2 h),但低血糖率也最高(4.0%)。三组血糖变异系数和6个月死亡率无显著差异。

要点

  • 模拟人工胰腺高强度组平均血糖8.1±2.2 mmol/L、达标率80.4%、达标时间17.5±4.2 h,均优于低强度组和优泌林组(均P=0.000)。
  • 高强度组低血糖率4.0%(313/7818)高于低强度组2.8%(211/7585)和优泌林组1.3%(108/8196),三组比较P=0.000。
  • 三组血糖变异系数和6个月死亡率无显著差异(P>0.05),6个月死亡率分别为优泌林组55.0%、低强度组45.0%、高强度组40.0%。
  • GRT系统每10分钟监测腹壁组织间液葡萄糖,可及时发现并纠正低血糖。
  • 三组患者入组24小时内血清肾上腺素、皮质醇和胰岛素抵抗指数均显著高于健康对照组。

适用人群与场景

  • 纳入标准:18-85岁、APACHE II评分>15、连续两次随机血糖≥11.1 mmol/L、糖化血红蛋白<0.065、入组后3天不能进食或仅接受肠外营养的ICU应激性高血糖患者。
  • 研究场所为上海市浦东新区浦南医院ICU,纳入时间为2015年1月1日至2017年6月30日。

诊断标准与关键阈值

  • 应激性高血糖诊断标准:连续两次随机血糖≥11.1 mmol/L。

处置流程与药物剂量

  • 高强度组:经模拟人工胰腺皮下注射诺和灵R,剂量为2/3剂量。
  • 低强度组:经模拟人工胰腺皮下注射诺和灵R,剂量为1/3剂量。
  • 优泌林组:皮下注射优泌林70/30调控血糖。
  • 模拟人工胰腺由Guardian实时血糖监测系统(GRT系统)、闭环控制算法和微泵组成。
  • 三组均使用GRT系统监测腹壁组织间液葡萄糖水平(等效于血糖水平),每10分钟一次。

红旗征与不能漏的情况

  • 高强度组低血糖率4.0%(313/7818),低强度组2.8%(211/7585),优泌林组1.3%(108/8196);使用GRT系统高频血糖监测可及时发现低血糖并协助纠正。

研究设计与关键结果

  • 前瞻性随机对照研究,纳入60例合格重症患者,每组20例;三组性别、年龄、APACHE II评分无显著差异。
  • 主要终点:优泌林组、低强度组、高强度组平均血糖分别为10.2±3.2、8.4±2.6、8.1±2.2 mmol/L,达标率分别为40.2%(3295/8196)、71.1%(5393/7585)、80.4%(6286/7818),达标时间分别为49.1±5.8、24.6±4.6、17.5±4.2小时,低血糖率分别为1.3%(108/8196)、2.8%(211/7585)、4.0%(313/7818),三组比较均P=0.000。
  • 血糖变异系数分别为优泌林组(29.4±3.7)%、低强度组(28.5±5.3)%、高强度组(26.1±4.6)%,6个月死亡率分别为55.0%、45.0%、40.0%,三组比较均P>0.05。
  • 三组入组24小时内血清肾上腺素、皮质醇和胰岛素抵抗指数均显著高于健康对照组。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为模拟人工胰腺可有效且安全地调控重症患者应激性高血糖,高强度调控在血糖调节方面可带来更好的疗效。
  • 作者认为使用GRT系统高频血糖监测可及时发现低血糖并帮助纠正。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore efficacy and safety of simulated artificial pancreas in modulating stress hyperglycemia in critically ill patients.

METHODS: A prospective randomized controlled study was performed. Seventy-two critically ill patients with stress hyperglycemia, aged 18-85 years, acute physiology and chronic health evaluation II (APACHE II) score over 15, two consecutive random blood glucose 11.1 mmol/L or higher, glycated hemoglobin (HbA1C) below 0.065, unable to eat food for 3 days after inclusion, or only accepting parenteral nutrition, admitted to intensive care unit (ICU) in Shanghai Punan Hospital of Pudong New District from January 1st, 2015 to June 30th, 2017 were enrolled. The patients were divided into three groups according to the random number table method, high-intensity group and low-intensity group were injected Novolin R (high-intensity group 2/3 dosage, low-intensity group 1/3 dosage) to modulate stress hyperglycemia by simulated artificial pancreas. Simulated artificial pancreas consisted of Guardian real time glucose monitoring system (GRT system), close-circle control algorithm and micro-pump; subcutaneous injection of Humulin 70/30 was applied to modulate stress hyperglycemia in humulin group. Real-time glucose levels of interstitial fluid in abdominal wall, equivalent to blood glucose levels, 10 minutes each time, were monitored by using of GRT system for all patients in three groups. Fasting serum levels of stress hormones including epinephrine and cortisol and insulin resistance index (IRI) were recorded within 24 hours after inclusion. Mean blood glucose, blood glucose variation coefficient, blood glucose target-reaching rate, blood glucose target-reaching time, hypoglycemia rate and 6-month mortality were measured. Twenty healthy adults from health administration department of the hospital were recruited as healthy control group.

RESULTS: A total of 60 eligible critically ill patients were included in this study, each group with 20 patients. There was no significant difference in gender, age, APACHE II scores among three groups. The levels of serum epinephrine, cortisol and IRI within 24 hours after inclusion in the three groups were significantly higher than those in healthy control group. The mean blood glucose levels of humulin group, low-intensity group, high-intensity group were decreased (mmol/L: 10.2±3.2, 8.4±2.6, 8.1±2.2), the blood glucose target-reaching rate were increased [40.2% (3 295/8 196), 71.1% (5 393/7 585), 80.4% (6 286/7 818)], the blood glucose target-reaching time were shortened (hours: 49.1±5.8, 24.6±4.6, 17.5±4.2), the hypoglycemia rates were increased respectively [1.3% (108/8 196), 2.8% (211/7 585), 4.0% (313/7 818)], with statistically significant differences (all P = 0.000). There was no significant difference in blood glucose variation coefficient and 6-month mortality among three groups [blood glucose variation coefficient: (29.4±3.7)%, (28.5±5.3)%, (26.1±4.6)%, 6-month mortality: 55.0%, 45.0%, 40.0%, all P > 0.05].

CONCLUSIONS: Simulated artificial pancreas could effectively and safely modulate stress hyperglycemia in critically ill patients, high-intensity modulation could bring about better efficacy in the regulation of hyperglycemia. High-frequency blood glucose monitoring by using GRT system could promptly identify hypoglycemia and help it to be corrected.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yang Z, Tao G, Guo M, et al. [Efficacy and safety of simulated artificial pancreas in modulating stress hyperglycemia in critically ill patients: a prospective randomized controlled study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29402368. doi:10.3760/cma.j.issn.2095-4352.2018.02.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。